Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.

Laboratorios Sophia

Status and phase

Not yet enrolling

Phase 1

Conditions

Healthy

Treatments

Drug: PRO-232

Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06352541

SOPH232-0824/I

Details and patient eligibility

About

This is a phase I study evaluating safety and tolerability through the incidence of unexpected adverse events and IOP measurement, as well as through the incidence of stinging after its administration, compared to placebo.

Full description

The variables to be evaluated include:

Primary (safety):

Unexpected adverse events
IOP

Primary (tolerability):

Stinging

Secondary (safety):

Expected and related adverse events
BCVA
Ocular surface stining

Secondary (tolerability):

Other ocular symptoms (foreign body sensation and tearing)

The operational definition states a difference under 15% in order to consider non inferior the safety and tolerability profile of PRO-232 compared to placebo.

Enrollment

28 estimated patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Having the ability to voluntarily give their signed informed consent.
Ophthalmologically and clinically healthy subjects.
Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.
Age between 18 to 45 years.
Male or female gender.
Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO [Tubal Ligation]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form [ICF]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.
Best corrected visual acuity (BCVA) of 20/30 or better in both eyes.
Corneal staining ≤ grade I on the Oxford Scale.
Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.

Exclusion criteria

History of hypersensitivity to fluoroquinolones, steroid anti-inflammatories, or any of the components of the drugs under investigation.
Use of ophthalmic medications from any pharmacological group.
Use of medications by any other route of administration.
Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or antibiotics by any route of administration in the last 30 days.
History of eye surgery in the last 6 months.
Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.
In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.
Having participated in any clinical research study 30 days prior to inclusion in this study.
Having previously participated in this same study.
History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.
Diagnosis of glaucoma or ocular hypertension.
Known diagnosis of liver or heart disease.
Presenting active inflammatory or infectious disease at the time of entry into the study.
Presenting unresolved lesions or traumas at the time of entry into the study.
Having been subjected to non-ophthalmological surgical procedures in the last 3 months.
Being or having an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.
Active smoking (specified as the consumption of cigarettes regardless of the amount and frequency, 4 weeks prior to study inclusion and during the intervention period of this study).
Active alcoholism (specified as the consumption of alcoholic beverages, regardless of the amount and frequency, 72 hours prior to study inclusion and during the intervention period of this study).

Elimination Criteria

Withdrawal of their consent to participate in the study (informed consent form).
Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).
Non-tolerability or hypersensitivity to any of the drugs under investigation.
Adherence < 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

28 participants in 2 patient groups, including a placebo group

PRO-232

Experimental group

Description:

* PRO-232. Moxifloxacin 0.5% y Dexamethasone Phosphate 0.1% Ophthalmic solution. * Dosage: 1 drop QID \[4\] (four times per day) for 7 days on right eye.

Treatment:

Drug: PRO-232

Placebo

Placebo Comparator group

Description:

* Placebo. Sodium Chloride. * Dosage: 1 drop QID \[4\] (four times per day) for 7 days on right eye.

Treatment:

Other: Placebo